# Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors

> **NCT05238818** · PHASE1 · UNKNOWN · sponsor: **XinWu** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic or Recurrent Gynecological Tumors

## Interventions

- **BIOLOGICAL:** Autologous Tumor Infiltrating Lymphocyte Injection (GT202)

## Key facts

- **NCT ID:** NCT05238818
- **Lead sponsor:** XinWu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2024-01
- **Final completion:** 2025-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238818, "Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05238818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*